Walnut oral immunotherapy for desensitisation of walnut and additional tree nut allergies (Nut CRACKER) : a single-centre, prospective cohort study

Copyright © 2019 Elsevier Ltd. All rights reserved..

BACKGROUND: The safety and efficacy of oral immunotherapy for tree nut allergy has not been demonstrated to date, and its effectiveness is complicated by the high prevalence of co-allergies to several nuts. This study aimed to investigate the use of walnut oral immunotherapy in the desensitisation of walnut and additional tree nuts in patients who are co-allergic to several nuts.

METHODS: In a single-centre, prospective cohort study (the Nut Co-Reactivity ACquiring Knowledge for Elimination Recommendations study) at the Institute of Allergy, Immunology, and Paediatric Pulmonology at the Yitzhak Shamir Medical Centre, we recruited patients aged 4 years or older who were allergic to walnut, with or without co-allergy to pecan, hazelnut, and cashew. The diagnosis of each food allergy was based on a positive skin prick test or specific serum IgE (≥0·35 kUA/L) to the corresponding nut together with a positive oral food challenge, unless an immediate (within 2 h of exposure) reaction in the past year had been documented. Patients with uncontrolled asthma or a medical contraindication to receive adrenaline were excluded. Patients were assigned to walnut oral immunotherapy or the control group (observation and strict dietary exclusion) on the basis of the order of presentation to the clinic. Oral immunotherapy began with a 4-day dose-escalation phase to establish the single highest tolerated dose, which was consumed daily at home for 24 days; subsequent monthly dose escalations were repeated until 4000 mg walnut protein was achieved. Patients who were desensitised to walnut continued to consume 1200 mg walnut protein daily for 6 months as maintenance. The primary outcome was walnut desensitisation (passing an oral food challenge with 4000 mg of walnut protein) at the end of the study, analysed by intention to treat. In patients who were co-allergic to pecan, hazelnut, and cashew, the proportion who achieved cross-desensitisation to these nuts in addition to walnut desensitisation was examined.

FINDINGS: 73 patients with a walnut allergy were enrolled between May 15, 2016, and Jan 14, 2018. 49 (89%) of 55 patients in the oral immunotherapy group were desensitised to walnut compared with none of 18 patients in the control group (odds ratio 9·2, 95% CI 4·3-19·5; p<0·0001). Following walnut desensitisation, all patients who were co-allergic to pecan (n=46) were also desensitised to pecan. Additionally, 18 (60%) of 30 patients who were co-allergic to hazelnut or cashew, and 14 (93%) of 15 patients who were co-allergic to hazelnut alone, were either fully desensitised or responded to treatment. 47 (85%) of 55 patients had an adverse reaction (mostly grade 1 or 2) during up-dosing in the clinic; eight patients required intramuscular epinephrine in response to a dose at home. Of 45 patients who had follow-up data for the maintenance phase, all maintained walnut desensitisation and one patient required epinephrine during this period.

INTERPRETATION: Walnut oral immunotherapy can induce desensitisation to walnut as well as cross-desensitisation to pecan and hazelnut in patients who have tree nut co-allergies, with a reasonable safety profile. A low daily dose of the allergen maintains desensitisation.

FUNDING: None.

Errataetall:

CommentIn: Lancet Child Adolesc Health. 2019 May;3(5):283-285. - PMID 30926370

Medienart:

E-Artikel

Erscheinungsjahr:

2019

Erschienen:

2019

Enthalten in:

Zur Gesamtaufnahme - volume:3

Enthalten in:

The Lancet. Child & adolescent health - 3(2019), 5 vom: 01. Mai, Seite 312-321

Sprache:

Englisch

Beteiligte Personen:

Elizur, Arnon [VerfasserIn]
Appel, Michael Y [VerfasserIn]
Nachshon, Liat [VerfasserIn]
Levy, Michael B [VerfasserIn]
Epstein-Rigbi, Na'ama [VerfasserIn]
Pontoppidan, Bo [VerfasserIn]
Lidholm, Jonas [VerfasserIn]
Goldberg, Michael R [VerfasserIn]

Links:

Volltext

Themen:

Allergens
Controlled Clinical Trial
Journal Article
Nut Proteins

Anmerkungen:

Date Completed 18.05.2020

Date Revised 18.05.2020

published: Print-Electronic

CommentIn: Lancet Child Adolesc Health. 2019 May;3(5):283-285. - PMID 30926370

Citation Status MEDLINE

doi:

10.1016/S2352-4642(19)30029-X

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM295484764